Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28280674 | 0.76 | MAOB (0.44) | LMNAL3MBTL1ALDH1A1TSHRMAOB | |
| SCHEMBL28837942 | 0.75 | CA1 (0.42) | NOX1 | |
| SCHEMBL29203313 | 0.73 | RAD51 (0.34) | NOX1 | |
| Benzaldehyde SCHEMBL29030084 | 0.70 | ALDH1A1 (0.54) | LMNAL3MBTL1ALDH1A1TSHRMAOB | |
| SCHEMBL8980035 | 0.69 | LMNA (0.50) | LMNAL3MBTL1ALDH1A1TSHRMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL16968445 | 0.67 | MAOB (0.58) | LMNAALDH1A1MAOBMEN1KMT2A | |
| SCHEMBL28286109 | 0.65 | TDP1 (0.38) | LMNAL3MBTL1ALDH1A1TSHRNPSR1 | |
| SCHEMBL17846299 | 0.65 | ALDH1A1 (0.37) | LMNAL3MBTL1ALDH1A1TSHRMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL28449979 | 0.65 | MAOB (0.55) | LMNAALDH1A1MAOBMEN1KMT2A | |
| SCHEMBL53708 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295162-A1 | SYNTHESIS OF NOVEL IMIPRIDONE DERIVATIVES AND THEIR EVALUATION FOR THEIR ANTICANCER ACTIVITY | SEMMELWEIS EGYETEM (HU) | 2023-09-21 | — | — | US | disclosed |
| US-10072057-B2 | Alternative nucleic acid molecules containing reduced uracil content and uses thereof | MODERNATX, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180009866-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-11 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072057-B2 | Alternative nucleic acid molecules containing reduced uracil content and uses thereof | RNMT, NSUN2, ADAR | LMNA 2314/4885L3MBTL1 839/4885ALDH1A1 2162/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | LMNA 571/4885L3MBTL1 279/4885ALDH1A1 2324/4885 |
| US-20230295162-A1 | SYNTHESIS OF NOVEL IMIPRIDONE DERIVATIVES AND THEIR EVALUATION FOR THEIR ANTICANCER ACTIVITY | IMPA1, REN, IGF1R | LMNA 1258/4885L3MBTL1 4428/4885ALDH1A1 38/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | LMNA 571/4885L3MBTL1 279/4885ALDH1A1 2324/4885 |
| US-20180009866-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | RNMT, NSUN2, ADAR | LMNA 2314/4885L3MBTL1 839/4885ALDH1A1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.